Advertisement
Canada markets open in 2 hours 39 minutes
  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CAD/USD

    0.7308
    -0.0013 (-0.17%)
     
  • CRUDE OIL

    82.87
    -0.49 (-0.59%)
     
  • Bitcoin CAD

    90,775.70
    +64.52 (+0.07%)
     
  • CMC Crypto 200

    1,433.86
    +9.76 (+0.69%)
     
  • GOLD FUTURES

    2,329.10
    -13.00 (-0.56%)
     
  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     
  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     
  • NASDAQ futures

    17,695.25
    +88.50 (+0.50%)
     
  • VOLATILITY

    15.82
    +0.13 (+0.83%)
     
  • FTSE

    8,083.50
    +38.69 (+0.48%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • CAD/EUR

    0.6835
    -0.0001 (-0.01%)
     

How Gilead Sciences plans to Beat Merck in Hepatitis C

Merck's Zepatier poses a new challenge to its best selling drug, but the risk might not be as big as you think.

This podcast was recorded on Feb. 3, 2016.